Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People whose breast cancer has been confirmed by a tissue sample (biopsy) to be a type called adenocarcinoma
- People whose breast cancer has been assessed as stage III (a measure of how far the cancer has spread locally)
- People whose breast cancer tests negative for a protein called HER2, based on specific laboratory test results
- People whose breast cancer has low or absent levels of hormone receptors (estrogen and progesterone), according to specific thresholds that vary depending on the tumour grade (confirm with trial site for exact details)
- People who are planned to receive the full standard cancer treatment in the Netherlands, including chemotherapy given before surgery (neoadjuvant chemotherapy)
- People who are able to use a mobile phone, tablet, laptop, or computer, and who understand the Dutch language
Who may not be able to join:
- People whose cancer has spread to distant parts of the body (distant metastases), as determined by staging tests carried out according to Dutch national guidelines
- People who are only receiving systemic treatment (such as chemotherapy or hormone therapy) after surgery, rather than before it
- People who are already taking part in another clinical trial that involves a treatment intervention at the same time as this study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 0205129111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To determine the effects of the standard (neo)adjuvant systemic treatment on health-related quality of life (HRQoL) for patients with stage III TNBC. Questionnaire 1.; To determine the effects of the standard (neo)adjuvant systemic treatment on health-related quality of life (HRQoL) for patients with stage III TNBC. Questionnaire 2.; To determine the effects of the standard (neo)adjuvant systemic treatment on health-related quality of life (HRQoL) for patients with stage III TNBC. Questionnaire 3.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.